-
FROM EVIDENCE GAPS TO LAUNCH READINESS: WHICH EVIDENCE UNCERTAINTIES RESTRICT PATIENT ACCESS?
Aug 11, 2026, 17:15 PM -
EU HTA IN PRACTICE: MEMBER STATE READINESS AND EARLY LESSONS FROM THE FIRST JCA REPORTS
Aug 11, 2026, 17:15 PM -
A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC AND HUMANISTIC BURDEN OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Aug 11, 2026, 17:15 PM -
PHARMACEUTICAL TURNOVER BY ANATOMICAL THERAPEUTIC CHEMICAL (ATC) MAIN GROUPS IN ESTONIA BETWEEN 2012 AND 2024: AN ANALYSIS UTILIZING STATE AGENCY OF MEDICINES STATISTICAL YEARBOOK DATA
Aug 11, 2026, 17:15 PM -
VALUE DATA STUDI: A MODULAR HOSPITAL-PHARMACY METHODOLOGY TO QUANTIFY COST SAVINGS FROM CLINICAL TRIAL DRUG MANAGEMENT WITHIN AN INTEGRATED PHARMACEUTICAL DATA ECOSYSTEM
Aug 11, 2026, 17:15 PM -
REPORTING POPULATION NORMS AND SOCIOECONOMIC INEQUALITIES IN SELF-REPORTED HEALTH USING EQ-5D-5L: RESULTS FROM MULTICOUNTRY GENERAL POPULATION SURVEYS
Aug 11, 2026, 17:15 PM -
BIOMARKERS ASSOCIATED WITH RISK OF SYSTEMIC COMPLICATIONS IN SJOGREN'S DISEASE: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:15 PM -
THE BIOSECURE EFFECT: EU MARKET ACCESS IMPLICATIONS FOR CHINA-ORIGINATED PD-(L)1 INHIBITORS
Aug 11, 2026, 17:15 PM -
CONVERSION-TO-OPEN SURGERY AVOIDED BY ROBOTIC-ASSISTED SURGERY IN SWEDISH COLORECTAL CANCER: A 10-YEAR NATIONAL-REGISTRY BUDGET-IMPACT ANALYSIS, 2015-2024
Aug 11, 2026, 17:15 PM -
CLAIMS-BASED LIPID-LOWERING THERAPY COVERAGE COMPARED TO CONVENTIONAL DRUG-SPECIFIC MEDICATION ADHERENCE AND PERSISTENCE METRICS
Aug 11, 2026, 17:15 PM -
SOCIO-ECONOMIC BURDEN OF ADHD: GLOBAL INSIGHTS AND PRELIMINARY FINDINGS FROM HONG KONG
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS ANALYSIS OF ADJUVANTED RSVPREF3 OA VACCINE IN ADULTS AGED =75 YEARS AND THE COMORBID POPULATION AGED 60-74 YEARS IN SWITZERLAND
Aug 11, 2026, 17:15 PM -
HEALTH IMPACT AND COST-EFFECTIVENESS OF DIGITAL MESSAGING NUDGES ON INFLUENZA VACCINE UPTAKE AMONG CHINESE OLDER ADULTS: A REAL-WORLD TRIAL
Aug 11, 2026, 17:15 PM -
GENERATIVE AI-ASSISTED REVIEW OF COST-EFFECTIVENESS EVIDENCE TO INFORM HEALTH TECHNOLOGY ASSESSMENT STRATEGY
Aug 11, 2026, 17:15 PM -
SOLAR: AN OBSERVATIONAL STUDY OF THE LONG-TERM EFFECTIVENESS OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN PEOPLE WITH CYSTIC FIBROSIS USING DATA FROM THE FRENCH CYSTIC FIBROSIS REGISTRY—IMPACT ON QUALITY OF LIFE AND HEALTH UTILITY VALUES
Aug 11, 2026, 17:15 PM -
FINANCIAL IMPACT OF BUNDLED CONTRACTS IN HEMODIALYSIS: A TOTAL COST OF OWNERSHIP (TCO) CASE STUDY OF A REGION IN SWEDEN
Aug 11, 2026, 17:15 PM -
UNLOCKING THE VALUE OF BIOLOGIC THERAPIES IN MULTIPLE MYELOMA: THE POTENTIAL OF ON-BODY INJECTORS TO IMPROVE HEALTHCARE EFFICIENCY AND SERVICE DELIVERY
Aug 11, 2026, 17:15 PM -
MOST FAVORED NATION (MFN) IN MOTION: NEW POLICY SIGNALS AND GLOBAL SPILLOVER EFFECTS
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS OF SAPIEN 3 VS. EVOLUT PRO/PRO+ FOR TRANSCATHETER AORTIC VALVE REPLACEMENT: AN ECONOMIC EVALUATION IN ISRAEL
Aug 11, 2026, 17:15 PM -
NAVIGATING HTA AND REIMBURSEMENT IN THE DACH REGION - A COMPARATIVE ANALYSIS OF NATIONAL PROCESSES AND EVIDENCE REQUIREMENTS WITH STRATEGIC IMPLICATIONS FOR MARKET ACCESS IN GERMANY, AUSTRIA AND SWITZERLAND
Aug 11, 2026, 17:15 PM
